VEGFA and choroidal neovascularization: In the United States, there are currently two anti-VEGF biosimilars FDA-approved for ophthalmic use: ranibizumab-nuna (Byooviz; Biogen—Cambridge, MA, USA and Samsung Bioepis—Incheon, South Korea), which was FDA-approved in 2021 for exudative AMD, ME due to RVO, and myopic choroidal neovascularization, and ranibizumab-eqrn (Cimerli; Coherus—Redwood City, CA, USA), which was FDA-approved in 2022 as the first interchangeable biosimilar to ranibizumab [119].